Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
| ▸ | HSD11B2 | P80365 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.36 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.35 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
| ▸ | KLK7 | P49862 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSK | P43235 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2290598 | 1.00 | SPHK1 (0.43) | SPHK1BRD4HSD11B2MAPTNR1H2 | |
| SCHEMBL7686350 | 0.88 | SPHK1 (0.41) | SPHK1BRD4HSD11B2DDB1CRBN | |
| SCHEMBL2617266 | 0.86 | SPHK1 (0.44) | SPHK1BRD4HSD11B2GPR119 | |
| SCHEMBL12522465 | 0.85 | SPHK1 (0.51) | SPHK1BRD4HSD11B2KLK7 | |
| SCHEMBL6487562 | 0.85 | SPHK1 (0.39) | SPHK1BRD4HSD11B2MAPTNR1H2 | |
| SCHEMBL2617265 | 0.85 | F2 (0.44) | SPHK1BRD4HSD11B2GPR119 | |
| SCHEMBL6487557 | 0.85 | SPHK1 (0.39) | SPHK1BRD4HSD11B2MAPTNR1H2 | |
| SCHEMBL2291830 | 0.85 | SMN1; SMN2 (0.40) | SPHK1BRD4HSD11B2MAPTKDM1A | |
| SCHEMBL2288435 | 0.85 | SPHK1 (0.39) | SPHK1BRD4HSD11B2MAPTNR1H2 | |
| SCHEMBL7040161 | 0.85 | BRD4 (0.40) | SPHK1BRD4HSD11B2NR1H2NR1H3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989480-B2 | Aryl amino acid derivatives as inhibitors for treating inflammation | DECODE GENETICS EHF (IS) | 2011-08-02 | — | — | US | disclosed |
| EP-2066800-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | Decode Genetics EHF (IS) | 2009-06-10 | — | — | EP | disclosed |
| WO-2008019306-A2 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS OF LTA4H (LEUKOTRIENE A4 HYDROLASE) FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2008-02-14 | — | — | WO | disclosed |
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF. (IS) | 2008-02-07 | — | — | US | disclosed |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2005-02-24 | — | — | US | disclosed |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2002-10-03 | — | — | US | disclosed |
| WO-2002000622-A2 | AMINOALCOHOL DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-01-03 | — | — | WO | disclosed |
| EP-1140849-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-10 | — | — | EP | disclosed |
| WO-2000040560-A1 | AMINOALCOHOL DERIVATIVES AND THEIR USE AS BETA 3 ADRENERGIC AGONISTS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080033024-A1 | ARYL AMINO ACID DERIVATIVES AS INHIBITORS FOR TREATING INFLAMMATION | LTA4H, LTB4R2, LTB4R | SPHK1 2199/4885BRD4 980/4885HSD11B2 1698/4885 |
| US-20020143034-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB1, ADRB2, ADRB3 | SPHK1 874/4885BRD4 483/4885HSD11B2 50/4885 |
| US-20050043358-A1 | Aminoalcohol derivatives and their use as beta 3 adrenergic agonists | ADRB2, ADRB1, ADRB3 | SPHK1 1034/4885BRD4 294/4885HSD11B2 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.